NASDAQ:EYPT - pSivida Stock Price, Price Target & More

$1.71 +0.19 (+12.50 %)
(As of 04/19/2018 03:24 PM ET)
Previous Close$1.52
Today's Range$1.50 - $1.80
52-Week Range$0.93 - $2.45
Volume1.09 million shs
Average Volume385,232 shs
Market Capitalization$65.24 million
P/E Ratio-3.37
Dividend YieldN/A
Beta1.1

About pSivida (NASDAQ:EYPT)

pSivida logopSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Durasert, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. It is also developing Durasert, which is in pre-clinical trials for the treatment of posterior segment uveitis; steroid implant for severe knee osteoarthritis; and TKI Insert, an injectable, bioerodible, sustained-release Durasert insert delivering a tyrosine kinase inhibitor for treatment of wet age-related macular degeneration. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Enigma Therapeutics Limited; and Nicox S.A. pSivida Corp. was founded in 1987 and is based in Watertown, Massachusetts.

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYPT
CUSIPN/A
Phone617-926-5000

Debt

Debt-to-Equity RatioN/A
Current Ratio3.21%
Quick Ratio3.21%

Price-To-Earnings

Trailing P/E Ratio-3.37
Forward P/E Ratio-3.29
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.54 million
Price / Sales10.27
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book5.03

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-18,480,000.00
Net Margins-882.37%
Return on Equity-205.82%
Return on Assets-144.60%

Miscellaneous

Employees22
Outstanding Shares45,300,000

How to Become a New Pot Stock Millionaire

pSivida (NASDAQ:EYPT) Frequently Asked Questions

What is pSivida's stock symbol?

pSivida trades on the NASDAQ under the ticker symbol "EYPT."

How were pSivida's earnings last quarter?

pSivida (NASDAQ:EYPT) issued its earnings results on Wednesday, February, 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.02. The business earned $0.93 million during the quarter, compared to analyst estimates of $0.48 million. pSivida had a negative return on equity of 205.82% and a negative net margin of 882.37%. View pSivida's Earnings History.

When is pSivida's next earnings date?

pSivida is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for pSivida.

What price target have analysts set for EYPT?

7 equities research analysts have issued 12-month target prices for pSivida's shares. Their predictions range from $3.00 to $13.00. On average, they anticipate pSivida's stock price to reach $7.2857 in the next year. View Analyst Ratings for pSivida.

What are Wall Street analysts saying about pSivida stock?

Here are some recent quotes from research analysts about pSivida stock:
  • 1. According to Zacks Investment Research, "EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA. " (4/17/2018)
  • 2. FBR & Co analysts commented, "Updosing phase completed in PALISADE—topline results in early 2018. Aimmune reported that almost (97%) all of the 554 enrolled 4-49yo peanut-allergic Phase 3 PALISADE patients have completed the updosing phase which starts the 6 month countdown to topline pivotal data release (early Q1:18). Aimmune stated that powering is above initial expectations. At this point, we believe no additional news, such as amendments to the safety protocol, is a likely signal for trial success." (6/14/2017)

Who are some of pSivida's key competitors?

Who are pSivida's key executives?

pSivida's management team includes the folowing people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 61)
  • Mr. Leonard S. Ross, VP of Fin., Chief Accounting Officer & Principal Financial Officer (Age 68)
  • Ms. Deborah A. Jorn, Exec. VP of Corp. & Commercial Devel. (Age 60)
  • Dr. Dario A. Paggiarino M.D., VP & Chief Medical Officer (Age 61)
  • Mr. Marty Nazzaro, Sr. VP of Operations

Has pSivida been receiving favorable news coverage?

News headlines about EYPT stock have been trending somewhat negative this week, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. pSivida earned a news impact score of -0.03 on Accern's scale. They also assigned news articles about the company an impact score of 47.01 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of pSivida?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is pSivida's stock price today?

One share of EYPT stock can currently be purchased for approximately $1.74.

How big of a company is pSivida?

pSivida has a market capitalization of $65.24 million and generates $7.54 million in revenue each year. The company earns $-18,480,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. pSivida employs 22 workers across the globe.

How can I contact pSivida?

pSivida's mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]


MarketBeat Community Rating for pSivida (EYPT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about pSivida and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

pSivida (NASDAQ:EYPT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for pSivida in the last 12 months. Their average twelve-month price target is $7.2857, suggesting that the stock has a possible upside of 326.07%. The high price target for EYPT is $13.00 and the low price target for EYPT is $3.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.2857$7.5714$7.5714$8.60
Price Target Upside: 326.07% upside552.71% upside588.31% upside593.55% upside

pSivida (NASDAQ:EYPT) Consensus Price Target History

Price Target History for pSivida (NASDAQ:EYPT)

pSivida (NASDAQ:EYPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018HC WainwrightReiterated RatingBuy$3.00MediumView Rating Details
12/15/2017B. RileySet Price TargetBuy$5.00MediumView Rating Details
12/11/2017Northland SecuritiesReiterated RatingBuy$10.00MediumView Rating Details
11/8/2017LaidlawInitiated CoverageBuy$5.00N/AView Rating Details
6/14/2017Ladenburg ThalmannSet Price TargetBuy$13.00MediumView Rating Details
6/14/2017FBR & CoReiterated RatingBuyHighView Rating Details
5/30/2017Rodman & RenshawInitiated CoverageBuy$8.00HighView Rating Details
(Data available from 4/19/2016 forward)

Earnings

pSivida (NASDAQ:EYPT) Earnings History and Estimates Chart

Earnings by Quarter for pSivida (NASDAQ:EYPT)

pSivida (NASDAQ:EYPT) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20181($0.15)($0.15)($0.15)
Q4 20181($0.10)($0.10)($0.10)

pSivida (NASDAQ EYPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.15)N/AView Earnings Details
2/7/2018Q2 2018($0.15)($0.13)$0.48 million$0.93 millionViewListenView Earnings Details
11/7/2017Q1 2018($0.15)($0.15)$0.74 million$0.39 millionViewN/AView Earnings Details
9/11/2017Q4 2017($0.16)($0.16)$0.48 million$0.70 millionViewN/AView Earnings Details
5/4/2017Q3 2017($0.15)($0.15)$0.36 million$0.59 millionViewListenView Earnings Details
11/7/2016Q1($0.19)($0.21)$0.30 million$0.28 millionViewListenView Earnings Details
9/12/2016Q4($0.13)($0.19)$2.40 million$0.30 millionViewListenView Earnings Details
5/5/2016Q3($0.20)($0.15)$1.75 million$0.32 millionViewN/AView Earnings Details
2/8/2016Q2 2016($0.15)($0.18)$1.25 million$0.53 millionViewN/AView Earnings Details
11/5/2015Q116($0.15)($0.17)$0.50 million$0.47 millionViewN/AView Earnings Details
9/9/2015Q415($0.14)($0.17)$0.60 million$0.41 millionViewN/AView Earnings Details
5/8/2015Q315($0.13)($0.17)$0.33 millionViewN/AView Earnings Details
2/5/2015($0.13)($0.14)$0.52 millionViewN/AView Earnings Details
11/7/2014Q3 14($0.12)$0.67$25.30 millionViewN/AView Earnings Details
9/9/2014Q414($0.15)($0.15)$0.29 millionViewN/AView Earnings Details
5/13/2014Q314($0.15)($0.03)$0.55 million$2.00 millionViewN/AView Earnings Details
2/7/2014Q214($0.13)($0.13)$430.00 million$0.5920 millionViewN/AView Earnings Details
11/12/2013Q1($0.14)$0.60 millionViewListenView Earnings Details
9/25/2013Q413($0.12)($0.17)$0.65 million$0.4920 millionViewN/AView Earnings Details
5/13/2013Q3 2013($0.12)$0.51 millionViewN/AView Earnings Details
2/6/2013Q2 2013($0.11)$0.63 million$0.5850 millionViewListenView Earnings Details
11/8/2012Q113($0.10)($0.11)ViewN/AView Earnings Details
9/24/2012Q4 2012($0.19)($0.11)ViewN/AView Earnings Details
5/9/2012Q3 2012($0.17)($0.13)ViewN/AView Earnings Details
2/8/2012Q2 2012($0.17)($0.13)ViewN/AView Earnings Details
11/7/2011Q1 2012($0.21)($0.12)ViewN/AView Earnings Details
9/12/2011Q4 2011($0.18)($0.01)ViewN/AView Earnings Details
5/10/2011Q3 2011($0.22)($0.13)ViewN/AView Earnings Details
2/9/2011Q2 2011$0.45($0.15)ViewN/AView Earnings Details
11/5/2010Q1 2011($0.14)($0.17)ViewN/AView Earnings Details
9/22/2010Q4 2010$0.68ViewN/AView Earnings Details
5/12/2010Q3 2010($0.19)($0.15)ViewN/AView Earnings Details
11/12/2009Q1 2010($0.09)ViewN/AView Earnings Details
9/24/2009Q4 2009($0.03)ViewN/AView Earnings Details
5/13/2009Q3 2009($0.04)ViewN/AView Earnings Details
2/11/2009Q2 2009($0.05)ViewN/AView Earnings Details
11/11/2008Q1 2009($0.03)ViewN/AView Earnings Details
9/26/2008Q4 2008($1.92)ViewN/AView Earnings Details
2/11/2008Q2 2008($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

pSivida (NASDAQ:EYPT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

pSivida (NASDAQ EYPT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.49%
Institutional Ownership Percentage: 10.68%
Insider Trading History for pSivida (NASDAQ:EYPT)

pSivida (NASDAQ EYPT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2018Ew Healthcare Partners, L.P.Major ShareholderBuy8,606,324$1.10$9,466,956.40View SEC Filing  
6/14/2017Nancy LurkerInsiderBuy56,700$1.76$99,792.0056,700View SEC Filing  
1/4/2016Leonard S. RossVPSell5,000$4.70$23,500.00View SEC Filing  
12/22/2015Leonard S. RossVPSell33,950$5.39$182,990.50View SEC Filing  
12/22/2015Paul AshtonCEOSell120,000$5.39$646,800.00440,741View SEC Filing  
10/1/2014Paul AshtonCEOSell10,000$4.27$42,700.00View SEC Filing  
9/2/2014Paul AshtonCEOSell10,000$4.78$47,800.00View SEC Filing  
8/1/2014Paul AshtonCEOSell10,000$4.37$43,700.00View SEC Filing  
7/1/2014Paul AshtonCEOSell10,000$4.32$43,200.00View SEC Filing  
6/19/2014Paul AshtonCEOSell7,000$4.00$28,000.00View SEC Filing  
6/17/2014Lori FreedmanVPSell7,900$4.00$31,600.00View SEC Filing  
6/17/2014Paul AshtonCEOSell7,700$4.00$30,800.00View SEC Filing  
6/13/2014Lori FreedmanVPSell11,700$4.02$47,034.00View SEC Filing  
6/13/2014Paul AshtonCEOSell11,800$4.02$47,436.00View SEC Filing  
10/1/2012Paul HopperDirectorBuy10,000$1.68$16,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

pSivida (NASDAQ EYPT) News Headlines

Source:
DateHeadline
pSivida (EYPT) Given a $5.00 Price Target by HC Wainwright AnalystspSivida (EYPT) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 19 at 12:16 PM
pSivida (EYPT) & Its Peers Head to Head SurveypSivida (EYPT) & Its Peers Head to Head Survey
www.americanbankingnews.com - April 18 at 3:04 AM
pSivida (EYPT) Upgraded to "Buy" by Zacks Investment ResearchpSivida (EYPT) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 18 at 12:34 AM
pSivida (EYPT) versus Its Rivals Financial SurveypSivida (EYPT) versus Its Rivals Financial Survey
www.americanbankingnews.com - April 15 at 5:15 PM
pSivida (EYPT) & Its Rivals Head-To-Head SurveypSivida (EYPT) & Its Rivals Head-To-Head Survey
www.americanbankingnews.com - April 13 at 1:18 PM
HC Wainwright Reaffirms "Buy" Rating for pSivida (EYPT)HC Wainwright Reaffirms "Buy" Rating for pSivida (EYPT)
www.americanbankingnews.com - April 13 at 10:37 AM
Head-To-Head Contrast: pSivida (EYPT) vs. Its RivalsHead-To-Head Contrast: pSivida (EYPT) vs. Its Rivals
www.americanbankingnews.com - April 13 at 3:13 AM
EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™
finance.yahoo.com - April 12 at 10:27 AM
pSivida (EYPT) PT Set at $3.00 by HC WainwrightpSivida (EYPT) PT Set at $3.00 by HC Wainwright
www.americanbankingnews.com - April 8 at 5:55 PM

SEC Filings

pSivida (NASDAQ:EYPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

pSivida (NASDAQ:EYPT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

pSivida (NASDAQ EYPT) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.